US Patent 11142573 Anti-Notch3 antibody
Patent 11142573 was granted and assigned to AVEO Pharmaceuticals on October, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+274 characters)
Article
Patent abstract
Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation and/or overexpression of Notch3.
Edits on 22 Jul, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 7 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111425730
Date of Patent
October 12, 2021
0Patent Application Number
201704280
Date Filed
April 28, 2017
0Official Website
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111425730
Date of Patent
October 12, 2021
0Patent Application Number
201704280
Date Filed
April 28, 2017
0Official Website
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 13 Oct, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 11142573 Anti-Notch3 antibody
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11142573
Date of patent
October 12, 2021
Patent application number
20170428
Date Filed
April 28, 2017
Find more entities like US Patent 11142573 Anti-Notch3 antibody
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
